Dao Tian Fu
Nessuna posizione attualmente
Profilo
Attualmente, Dao Tian Fu occupa la posizione di presidente di RemeGen Co. In precedenza il dottor Fu è stato Manager-Quality Control & Research presso Neose Pharmaceuticals, Inc., Executive Director & Vice President presso Livzon Pharmaceutical Group, Inc. e General Manager presso Livzon MABPharm Inc. (una filiale della Livzon Pharmaceutical Group, Inc.), vicepresidente della ricerca alla Genzyme Corp. e direttore della divisione Primedica alla rEVO Biologics, Inc. Ha ricevuto un dottorato dalla Iowa State University e una laurea presso l'Università di Shandong.
Precedenti posizioni note di Dao Tian Fu
Società | Posizione | Fine |
---|---|---|
REMEGEN CO., LTD. | President | 12/05/2023 |
LIVZON PHARMACEUTICAL GROUP INC. | Director/Board Member | 27/09/2019 |
Livzon MABPharm Inc.
Livzon MABPharm Inc. Pharmaceuticals: MajorHealth Technology Part of ZHU HAI Livzon Biologics Ltd., Livzon MABPharm Inc. researches, develops, and sells biopharmaceutical products and antibody drugs. The private company is based in Zhuhai, China. | Chief Executive Officer | 01/09/2019 |
EPIRUS BIOPHARMACEUTICALS, INC. | Director/Board Member | 25/07/2016 |
REVO BIOLOGICS INC | Corporate Officer/Principal | 01/01/2001 |
Formazione di Dao Tian Fu
Iowa State University | Doctorate Degree |
Shandong University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
LIVZON PHARMACEUTICAL GROUP INC. | Health Technology |
LUNGLIFE AI, INC. | Health Services |
EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
REMEGEN CO., LTD. | Health Technology |
Aziende private | 5 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Neose Pharmaceuticals, Inc. | |
rEVO Biologics, Inc.
rEVO Biologics, Inc. BiotechnologyHealth Technology rEVO Biologics, Inc. engages in the development and commercialization of specialty therapeutics to address unmet medical needs in patients with rare, life-threatening conditions. Its products include ATryn, which prevents blood clots during and after surgery and childbirth for patients with hereditary antithrombin deficiency. The company was founded in February 1993 and is headquartered in Framingham, MA. | Health Technology |
Livzon MABPharm Inc.
Livzon MABPharm Inc. Pharmaceuticals: MajorHealth Technology Part of ZHU HAI Livzon Biologics Ltd., Livzon MABPharm Inc. researches, develops, and sells biopharmaceutical products and antibody drugs. The private company is based in Zhuhai, China. | Health Technology |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Dao Tian Fu